Lead Product(s): Eltanolone
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2020
Substantial reduction in PMDD symptoms was achieved across the patient population, but, in comparison to placebo, primary and secondary endpoints were not statistically significant.